Lirafugratinib
Product Sizes
10 mg
£ POA
HY-147250-10MG
50 mg
£ POA
HY-147250-50MG
5 mg
£ POA
HY-147250-5MG
25 mg
£ POA
HY-147250-25MG
100 mg
£ POA
HY-147250-100MG
10mM/1mL
£ POA
HY-147250-10MM
1 g
£ POA
HY-147250-1G
About this Product
- SKU:
- HY-147250
- Additional Names:
- RLY-4008
- CAS Number:
- 2549174-42-5
- Extra Details:
- Lirafugratinib (RLY-4008) is an orally active; irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].
- Molecular Weight:
- 509.53
- Purity:
- 99.67
- References:
- [1]Vivek Subbiah, et al. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 Sep 6;13(9):2012-2031.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Protein Tyrosine Kinase/RTK
